Urine markers for detection and surveillance of bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 222-229

  Xylinas, Evanguelos ^a   Kluth, Luis A ^a   Rieken, Malte ^a   Karakiewicz, Pierre I ^c   Lotan, Yair ^d   Shariat, Shahrokh F ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biomarker; Bladder cancer; Detection; Molecular marker; Surveillance; Urine; Urothelial carcinoma

Indexed keywords

AURORA A KINASE; BLADDER TUMOR ANTIGEN; CYTOKERATIN 19 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DD23; NUCLEAR MATRIX PROTEIN; NUCLEAR MITOTIC APPARATUS PROTEIN 22; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BLCA 1; TRANSCRIPTION FACTOR BLCA 4; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER CANCER DETECTION KIT; CANCER ELISA KIT; CANCER EPIDEMIOLOGY; CANCER SCREENING; CELL ASSAY; CYSTOSCOPY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY; BLADDER TUMOR; HUMAN; PROCEDURES; SENSITIVITY AND SPECIFICITY; URINE;

CARCINOMA, TRANSITIONAL CELL; EARLY DETECTION OF CANCER; HUMANS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84897064727     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.001     Document Type: Review

References (89)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Sievert K.D., Amend B., Nagele U., et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 2009, 27:295-300.
3. Burger M., Catto J.W., Dalbagni G., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013, 63:234-241.
4. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
5. Lotan Y., Kamat A.M., Porter M.P., et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 2009, 115:4096-4103.
6. Lotan Y., Svatek R.S., Malats N. Screening for bladder cancer: a perspective. World J Urol 2008, 26:13-18.
7. Shariat SF, Lotan Y, Vickers A, et al: Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010;28:389-400.
8. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18; [discussion 118].
9. Karakiewicz P.I., Benayoun S., Zippe C., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006, 97:997-1001.
10. Herr H.W. Words of wisdom: rethinking screening for breast cancer and prostate cancer. Eur Urol 2010, 57:540.
11. Steiner H., Bergmeister M., Verdorfer I., et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int 2008, 102:291-296.
12. Larre S., Catto J.W., Cookson M.S., et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 2013, 63:1049-1058.
13. Kamat A.M., Hegarty P.K., Gee J.R., et al. ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013, 63:4-15.
14. Lotan Y, Elias K, Svatek RS, et al: Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009;182:52-57; [discussion 58].
15. Vickers A.J., Bennette C., Kibel A.S., et al. Who should be included in a clinical trial of screening for bladder cancer? A decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial. Cancer 2013, 119:143-149.
16. Schmitz-Dräger B.J., Fradet Y., Grossman H.B. Bladder cancer markers in patient management: the current perspective. World J Urol 2008, 26:1-3.
17. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
18. Landman J., Chang Y., Kavaler E., et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998, 52:398-402.
19. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999, 162:53-57.
20. Mahnert B., Tauber S., Kriegmair M., et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer?. Clin Chem Lab Med 2003, 41:104-110.
21. Hughes J.H., Katz R.L., Rodriguez-Villanueva J., et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999, 20:285-290.
22. Soloway M.S., Briggman V., Carpinito G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996, 156:363-367.
23. Shariat S.F., Marberger M.J., Lotan Y., et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006, 176:919-926. [discussion 926].
24. Hutterer G.C., Karakiewicz P.I., Zippe C., et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int 2008, 101:561-565.
25. Barbieri C.E., Cha E.K., Chromecki T.F., et al. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. BJU Int 2012, 109:685-690.
26. Shariat S.F., Savage C., Chromecki T.F., et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 2011, 117:2892-2897.
27. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005, 173:1518-1525.
28. Boman H., Hedelin H., Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002, 167:80-83.
29. Sánchez-Carbayo M., Herrero E., Megías J., et al. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999, 162:1951-1956.
30. Poulakis V., Witzsch U., De Vries R., et al. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 2001, 88:692-701.
31. Grossman H.B., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. J Am Med Assoc 2006, 295:299-305.
32. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. J Am Med Assoc 2005, 293:810-816.
33. Sarosdy M.F., Hudson M.A., Ellis W.J., et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997, 50:349-353.
34. Konety B.R., Getzenberg R.H. Urine based markers of urological malignancy. J Urol 2001, 165:600-611.
35. Kinders R., Jones T., Root R., et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998, 4:2511-2520.
36. Malkowicz S.B. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000, 27:63-73. [ix].
37. Lokeshwar V.B., Soloway M.S. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 2001, 165:1067-1077.
38. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005, 66:35-63.
39. Wiener H.G., Mian C., Haitel A., et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 1998, 159:1876-1880.
40. Leyh H., Marberger M., Conort P., et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999, 35:52-56.
41. Pode D., Shapiro A., Wald M., et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999, 161:443-446.
42. Sözen S., Biri H., Sinik Z., et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999, 36:225-229.
43. Ramakumar S., Bhuiyan J., Besse J.A., et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999, 161:388-394.
44. Nasuti J.F., Gomella L.G., Ismial M., et al. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999, 21:27-29.
45. Heicappell R., Wettig I.C., Schostak M., et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999, 35:81-87.
46. Serretta V., Pomara G., Rizzo I., et al. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur Urol 2000, 38:419-425.
47. Giannopoulos A., Manousakas T., Mitropoulos D., et al. Comparative evaluation of the BTA stat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2000, 55:871-875.
48. Raitanen M.P., Marttila T., Nurmi M., et al. Human complement factor H related protein test for monitoring bladder cancer. J Urol 2001, 165:374-377.
49. Babjuk M., Kostírová M., Mudra K., et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002, 41:34-39.
50. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004, 172:1123-1126.
51. Babjuk M., Soukup V., Pesl M., et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008, 71:718-722.
52. Ellis W.J., Blumenstein B.A., Ishak L.M., et al. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 1997, 50:882-887. The Multi Center Study Group.
53. Glas A.S., Roos D., Deutekom M., et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003, 169:1975-1982.
54. van Rhijn B.W.G., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005, 47:736-748.
55. Lokeshwar V, Habuchi T, Grossman H, et al: Cytology and tumor markers: Tumor markers beyond cytology, In: Soloway MS, Carmack A, Khoury S. editors Bladder Tumors Health Publication Ltd, 2006.
56. Sánchez-Carbayo M., Herrero E., Megías J., et al. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. Urology 1999, 54:656-661.
57. Sharp J.D., Hausladen D.A., Maher M.G., et al. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci 2002, 7:e36-e41.
58. Schultz I.J., Witjes J.A., Swinkels D.W., et al. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 2006, 368:20-32.
59. Margulis V., Lotan Y., Shariat S.F. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008, 26:59-65.
60. Shariat S.F., Casella R., Khoddami S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004, 171:626-630.
61. Horstmann M., Bontrup H., Hennenlotter J., et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 2010, 28:399-404.
62. Myers-Irvin J.M., Landsittel D., Getzenberg R.H. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005, 174:64-68.
63. Konety B.R., Nguyen T.S., Dhir R., et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000, 6:2618-2625.
64. Van Le T.S., Miller R., Barder T., et al. Highly specific urine-based marker of bladder cancer. Urology 2005, 66:1256-1260.
65. Van Le T.S., Myers J., Konety B.R., et al. Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res 2004, 10:1384-1391.
66. Konety B.R., Nguyen T.S., Brenes G., et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000, 164:634-639.
67. Nisman B., Barak V., Shapiro A., et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002, 94:2914-2922.
68. Sánchez-Carbayo M., Urrutia M., González de Buitrago J.M., et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001, 92:2820-2828.
69. Fradet Y., Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997, 4:400-405.
70. Beiche B., Ebert T., Schmitz-Dräger B. Immunzytologie in der Diagnostik des Urothelkarzinoms-ein reproduzierbares Testverfahren?. Urologe A 2002, 45.
71. Mian C., Pycha A., Wiener H., et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999, 161:1486-1489.
72. Olsson H., Zackrisson B. Immunocyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001, 35:280-282.
73. Vriesema J.L., Atsma F., Kiemeney L.A., et al. Diagnostic efficacy of the immunocyt test to detect superficial bladder cancer recurrence. Urology 2001, 58:367-371.
74. Pfister C., Chautard D., Devonec M., et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003, 169:921-924.
75. Cha E.K., Tirsar L.A., Schwentner C., et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 2012, 61:185-192.
76. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008, 26:646-651.
77. Gofrit O.N., Zorn K.C., Silvestre J., et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008, 26:246-249.
78. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169:2101-2105.
79. Schlomer B.J., Ho R., Sagalowsky A., et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010, 183:62-67.
80. Lotan Y., Bensalah K., Ruddell T., et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008, 179:2164-2169.
81. Bonner R.B., Liebert M., Hurst R.E., et al. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker network for bladder cancer. Cancer Epidemiol Biomarkers Prev 1996, 5:971-978.
82. Sawczuk I.S., Pickens C.L., Vasa U.R., et al. DD23 biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002, 7:185-190.
83. Gilbert S.M., Veltri R.W., Sawczuk A., et al. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology 2003, 61:539-543.
84. Park H.S., Park W.S., Bondaruk J., et al. Quantitation of aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008, 100:1401-1411.
85. Hoque M.O., Begum S., Topaloglu O., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006, 98:996-1004.
86. Renard I., Joniau S., van Cleynenbreugel B., et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010, 58:96-104.
87. Yu J., Zhu T., Wang Z., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007, 13:7296-7304.
88. Reinert T., Borre M., Christiansen A., et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One 2012, 7:e46297.
89. Reinert T., Modin C., Castano F.M., et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011, 17:5582-5592.